Is AIP a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on AI and chiplet demand tailwind, with revenue (q1 2026 quarterly) at ~$22.9 million, up ~39% year over year. The bear case rests on arteris is unprofitable on a GAAP basis and trades at a steep price-to-sales multiple (well above 20x) after the stock rose sharply over the past year, which leaves little room for disappointment. Analysts covering it are spread from $35.00 to $40.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Arteris is unprofitable on a GAAP basis and trades at a steep price-to-sales multiple (well above 20x) after the stock rose sharply over the past year, which leaves little room for disappointment. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $35.00, +28.7% from the $27.20 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

AI and chiplet demand tailwind. As chips get more complex and shift toward multi-die chiplet designs, the interconnect fabric Arteris licenses becomes harder to build in-house and more valuable. The most optimistic analyst target on AIP is $40.00, +47.1% from the $27.20 price. That figure is only reachable if this thesis works close to its best case.

Arteris is unprofitable on a GAAP basis and trades at a steep price-to-sales multiple (well above 20x) after the stock rose sharply over the past year, which leaves little room for disappointment. Royalty revenue depends on customers actually shipping chips, so it is exposed to the semiconductor cycle and to design cancellations or delays. The customer base is concentrated among a relatively small number of large chipmakers, and it competes with far larger EDA and IP vendors such as Cadence and Synopsys, plus the risk that big customers build interconnect in-house. Ongoing stock-based compensation dilutes shareholders, and a planned CFO transition in 2026 adds some management-continuity uncertainty. The most pessimistic published target is $35.00, +28.7% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Arteris sells the plumbing that connects the pieces of a modern chip.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (AI and chiplet demand tailwind) stalling in the reported numbers rather than in the narrative, the risk above (arteris is unprofitable on a GAAP basis and trades at a steep price-to-sales multiple (well above 20x) after the stock rose sharply over the past year, which leaves little room for disappointment) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

AIP is the Nasdaq ticker for Arteris, Inc., a semiconductor system IP company based in Campbell, California. It licenses network-on-chip (NoC) interconnect and related IP that chip designers use to connect the blocks inside a system-on-chip. Its technology has shipped in more than 4 billion devices across AI, automotive, and consumer markets.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is rapid growth in contracts and royalties driven by AI and chiplet demand and a very high gross margin. The bear case is that the company is still unprofitable and trades at a rich price-to-sales multiple after a large run-up. Weigh both against your own portfolio.

Arteris earns money in two layers. First, it charges license fees for its network-on-chip and system IP, tracked as annual contract value (ACV). Second, it collects per-unit royalties each time a customer ships a chip containing that IP. The royalty stream compounds over time as more designs reach production, which is why the company reports combined ACV plus royalties alongside revenue.